Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population

Applied Health Economics and Health Policy

Volumn 9, Issue 5, 2011, Pages 293-303

  Kirson, Noam Y ^a   Birnbaum, Howard G ^a   Ivanova, Jasmina I ^a   Waldman, Tracy ^a   Joish, Vijay ^b   Williamson, Todd ^b  

^a ANALYSIS GROUP   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

Cost of illness; Pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN;

ADULT; ARTICLE; CARDIOVASCULAR SYSTEM; CHI SQUARE TEST; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEALTH CARE COST; HEART CATHETERIZATION; HEMIPLEGIA; HOSPITAL PATIENT; HOSPITAL SERVICE; HUMAN; INSURANCE; INTERNATIONAL CLASSIFICATION OF DISEASES; LEUKEMIA; LIVER DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTPATIENT CARE; PARAPLEGIA; PRIVATE HEALTH INSURANCE; PULMONARY HYPERTENSION; RESPIRATORY SYSTEM; SENSITIVITY ANALYSIS; UNITED STATES; WILCOXON SIGNED RANKS TEST;

ADOLESCENT; ADULT; FEMALE; HEALTH CARE COSTS; HUMANS; HYPERTENSION, PULMONARY; INSURANCE, HEALTH; MALE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

EID: 80052254608     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11592430-000000000-00000     Document Type: Article

References (24)

1. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/ AHA 2009 expert consensus document on pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53 (17): 1573-619
2. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103-10 (Pubitemid 351194756)
3. Peacock AJ. Treatment of pulmonary hypertension. BMJ 2003; 326: 835-6
4. Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis 2002; 45 (3): 213-24 (Pubitemid 36139817)
5. Benedict N, Seybert A, Mathier M. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007; 29 (10): 2134-53 (Pubitemid 350138566)
6. Murali S. Pulmonary arterial hypertension. Curr Opin Crit Care 2006; 12: 228-34 (Pubitemid 44365951)
7. SimonneauG,Galie N, Rubin LJ, et al.Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5-12S
8. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009 Jun 30; 54 (1 Suppl.): S43-54
9. National Institute for Health and Clinical Excellence. Clinical and cost effectiveness of treatments for pulmonary arterial hypertension (PAH) within their licensed indications. London: NICE, 2007 [online]. Available from URL: Http:// www.nice.org.uk/nicemedia/pdf/PAHassessmentreport.pdf [Accessed 2009 Nov 20]
10. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improved functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108 (17): 2066-9 (Pubitemid 37337580)
11. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24 (6): 1007-10 (Pubitemid 39642293)
12. Angalakuditi M, Edgell E, Beardsworth A, et al. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. J Med Econ 2010; 13 (3): 393-402
13. Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-9 (Pubitemid 47074013)
14. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 1527-38 (Pubitemid 351508372)
15. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle pulmonary circulation unit: State of the art and clinical and research implications. Circulation 2009; 120: 992-1007
16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40 (5): 373-83 (Pubitemid 17055592)
17. Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1993; 46 (10): 1075-9
18. US Department of Labor, Bureau of Labor Statistics. Consumer price index for medical care services, 2009 [online]. Available from URL: Http://www.bls.gov/cpi/ [Accessed 2009 Nov 23]
19. Einarson TR, Granton JT, Vicente C, et al. Costeffectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: A Canadian analysis. Can Respir J 2005 Nov-Dec; 12 (8): 419-25 (Pubitemid 43109393)
20. Wilkens H, Grimminger F, Hoeper M, et al. Burden of pulmonary arterial hypertension in Germany. Respir Med 2010 Jun; 104 (6): 902-10
21. Macchia A, Marchioli R, Marfisi R, et al. Ameta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. Am Heart J 2007; 153: 1037-47 (Pubitemid 46809838)
22. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 2008; 118: 1195-201
23. Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010 Sep; 31 (17): 2080-6
24. Chen YF, Jowett S, Barton P, et al. Clinical and costeffectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: A systematic review and economic evaluation. Health Technol Assess 2009 Oct; 13 (49): 1-320